Receptor activator of nuclear factor kappa B ligand serum and synovial fluid level. A comparative study between rheumatoid arthritis and osteoarthritis

Rheumatology International

Volumn 32, Issue 6, 2012, Pages 1589-1596

  Ellabban, Abdou S ^a   Kamel, Shereen Refaat ^a   Ahmed, Shimaa S ^a   Osman, Ashraf M ^b  

^a Minia University   (Egypt)

^b MINIA UNIVERSITY   (Egypt)

Author keywords

Osteoarthritis; Receptor activator of nuclear factor kappa B ligand; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; RHEUMATOID FACTOR;

ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; JOINT SWELLING; MALE; MORNING STIFFNESS; OSTEOARTHRITIS; PAIN ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RATING SCALE; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID LEVEL; VARUS DEFORMITY;

ADULT; ARTHRALGIA; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; EGYPT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KNEE JOINT; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; PREDICTIVE VALUE OF TESTS; QUESTIONNAIRES; RANK LIGAND; SEVERITY OF ILLNESS INDEX; SYNOVIAL FLUID; YOUNG ADULT;

EID: 84863863689     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-011-1831-0     Document Type: Article

References (32)

1. Rojkovich B, Poor G (2002) Prognostic factors in rheumatoid arthritis. Orv Hetil 143(35):2019-2026
2. Harris ED (1990) Rheumatoid arthritis; Pathophysiology and implications for therapy. N Engl J Med 322:1277-1289
3. Sambrook PN, Eisman JA, Champion GD, Pocock NA, Eberl S, Yeates MG (1987) Determinants of axial bone loss in rheumatoid arthritis. Arthritis Rheum 30:721-728
4. Gough AKS, Lilley J, Eyre S, Holder RL, Emery P (1994) Generalized bone loss in patients with early rheumatoid arthritis occurs early and relates to disease activity. Lancet 344:23-27
5. Gravallese EM, Manning C, Tsay A et al (2000) Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 43:250-258
6. Kotake S, Udagawa N, Hakoda M, Mogi M, Yano K, Tsuda E et al (2001) Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 44:1003-1012
7. Romas E, Gillespie MT, Martin TJ (2002) Involvement of receptor activator of NF kappa B ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone 30:340-346
8. Lawerence RC, Helmock CG, Arnett FC et al (1998) Estimates of the prevalence of arthritis and selected musculskeletal disorders in the United States. Arthritis Rheum 41:778-799
9. Lacey DL, Timms E, Tan HL et al (1998) Osteoprotegrin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176
10. David RH (2007) Inflammatory cells and bone loss in rheumatoid arthritis. Arthritis Res & Therapy 9:104
11. Arnett FC, Edworthy SM, Bloch DA et al (1987) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324
12. Altman R, Asch E, Bloch D et al (1986) The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the knee. Arthritis Rheum 29:1039-1049
13. Ritchie DM, Boyle JA, Mclnnes JM et al (1968) Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 37:393-406
14. Ferraz MB, Quaresma MR, Aquino LR et al (1990) Reliability of pain scales in the assessment of literate and illiterate patients with rheumatoid arthritis. J Rheumatol 17(8):1022-1024
15. Fries JF, Spitz P, Kraines G et al (1980) Measurement of patient outcome in Arthritis. Arthritis Rheum 23:137-145
16. Prevoo MLL, van't Hof MA, Kuper HH et al (1995) Modified disease activity scores that include twenty-eight-joint counts. Arthritis Rheum 38:44-48
17. Bellamy N, Buchanan WW, Goldsmith CH et al (1988) Validation of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15:1833-1840
18. Trofimov S, Pantsulaia I, Tobyliansky E et al (2004) Circulating levels of receptor activator of NF kappa B ligand-osteoprotegrinmacrophage-colony stimulating factor in a presumably healthy human population. Eur J Endocrinol 11:150-305
19. Van der Heijde D (1999) How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 26:743-745
20. Kellgren JH, Lawrence JS (1957) Radiological assessment of osteo-arthrosis. Ann Rheum Dis 16:494-502
21. Yasuda H, Shima N, Nakagawa N et al (1998) Osteoclast differentiation factor is a ligand for osteoprotegrin/osteoclastogenesis inhibitory factor (OCIF) and is identical to TRANCE/RANKL. Pro Natl acad Sci USA 95:3597-3602
22. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A et al (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397: 315-323
23. Simonet WS, Lacey DL, Dunstan CR et al (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-319
24. Kong Y-Y, Feige U, Sarosi I et al (1999) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402:304-309
25. Minenna G, D'Amore S, Maggiolini P, Scagliusi P, D'Amore M (2005) RANKL/RANK, OPG and OPT in a group of patients affected by chronic arthritis. Preliminary report Recenti Prog Med 96(9):431-432
26. Crotti TN, Smith MD, Weedon H et al (2002) Receptor activator NF-kappa B ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis 61:1047-1054
27. Skoumal M, Kolarz G, Haberhauer G et al. (2005) Osteoprotegerine and the receptor activator of NF-Kappa B ligand in serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis. Rheumatol Int 26(1): 63-69. (Epub May 12)
28. Krystufkova O, Niederlova J, Senolt V et al. (2003) OPG and RANKL in serum and synovial fluids of patients with rheumatoid arthritis, osteoarthritis and spondylarthropathy. Arthritis Res Ther 5(Suppl 1):102
29. Haynes DR, Crotti TN, Loric M et al (2001) Osteoprotegerin and receptor activator of nuclear factor kappa B ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology 40:623-630
30. Komuro H, Olee T, Kühn K et al (2001) The osteoprotegerin/receptor activator of nuclear factor kappa B/receptor activator of nuclear factor kappaB ligand system in cartilage. Arthritis Rheum 44(12):2768-2776
31. Bekker PJ, Holloway D, Nakanishi A et al (2001) The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 16:348-360
32. Georg S (2007) Erosive Arthritis. Arthritis Res Ther. 9 (Supp), BioMed Central, Ltd